STOCK TITAN

Moleculin Biotech CFO acquires 362 shares on conversion

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) Chief Financial Officer Jonathan P. Foster exercised 362 restricted stock units into 362 common shares on November 16, 2026; the units convert one-for-one. 89 shares were withheld for payment of taxes at $7.14 per share upon vesting. The table reports 70,492 restricted stock units following the derivative transaction. No Rule 10b5-1 plan is reported.

Insider Foster Jonathan P.
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F1, F3, F4 362 $0.00 $0.00
Exercise Common Stock F1 362 -- --
Tax Withholding Common Stock F2 89 $7.14 $635.46
Holdings After Transaction: Restricted Stock Units — 70,492 units (Direct); Common Stock — 20,506 shares (Direct)
Holdings Before and After: Restricted Stock Units, 70,854 to 70,492 units (Direct); Common Stock, 20,233 to 20,506 shares (Direct)
Footnotes (4)
  1. F1. Restricted stock units convert into common stock on a one-for-one basis.
  2. F2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
  3. F3. The restricted stock unit set forth in this table vests as follows: (i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months.
  4. F4. Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
Restricted stock units exercised 362 units November 16, 2026
Common shares acquired 362 shares On conversion of restricted stock units on November 16, 2026
Shares withheld for taxes 89 shares Upon vesting on November 16, 2026
Price per share $7.14 per share Shares withheld for payment of taxes
Restricted stock units following transaction 70,492 units Reported following the derivative transaction
Vesting on grant 50% Restricted stock unit vesting schedule
Remaining vesting installments 18 installments The remaining 50% vests in equal installments over 18 months
Restricted stock units financial
"362 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"a contingent right to receive one share of Company common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did MBRX CFO Jonathan P. Foster acquire from restricted stock units?

Foster converted 362 restricted stock units into 362 common shares on November 16, 2026, on a one-for-one basis.

How many MBRX shares were withheld for taxes from Jonathan P. Foster's vesting?

89 shares were withheld for payment of taxes at $7.14 per share upon vesting on November 16, 2026.

What was the vesting schedule for Jonathan P. Foster's MBRX restricted stock units?

50% vested on grant, with the remaining 50% in 18 equal installments over 18 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Foster Jonathan P.

(Last)(First)(Middle)
C/O MOLECULIN BIOTECH, INC.
5300 MEMORIAL DR., SUITE 950

(Street)
HOUSTON TEXAS 77007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M362A(1)20,595D
Common Stock11/16/2026F89(2)D$7.1420,506D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)11/16/2026M362 (3) (4)Common Stock362$070,492D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
3. The restricted stock unit set forth in this table vests as follows: (i) 50% on grant; and (ii) 50% in 18 equal installments over 18 months.
4. Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
/s/ Jonathan P. Foster11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading